HighTower Advisors
DMII

HighTower Advisors’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

HighTower Advisors’s Portfolio DMII Stock Details DMII Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.7M Sell
566,614
-148,000
-21% -$1.49M 0.01% 1186
2026
Q1 		$7.12M Sell
714,614
-75,000
-9% -$747K 0.01% 1032
2025
Q4 		$7.82M Buy
+789,614
New +$7.81M 0.01% 967

Other funds holding DMII

KIM
Karpus Investment Management Pittsford, New York $3.48B AUM 10.49% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.07B AUM 78.71% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $11.4B AUM 5.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
TCM
Tenor Capital Management New York $7.09B AUM 3.55% 1-Year Est. Return

HighTower Advisors's DMII Position: Q2 2026 in Review

HighTower Advisors reduced its Drugs Made In America Acquisition II Corp (DMII) stake by 21% in Q2 2026, selling an estimated $1.49M and leaving 566,614 shares worth $5.7M. The position accounts for 0.01% of the portfolio, ranked #1186.

HighTower Advisors first reported a position in DMII in Q4 2025 and has held it in 3 quarters since. The position peaked at $7.82M in Q4 2025. 69 funds tracked by Wall St. Rank hold DMII as of Q2 2026.

  • HighTower Advisors held 566,614 shares of Drugs Made In America Acquisition II Corp worth $5.7M as of Q2 2026.
  • HighTower Advisors sold 148,000 Drugs Made In America Acquisition II Corp shares in Q2 2026, an estimated $1.49M.
  • Drugs Made In America Acquisition II Corp made up 0.01% of HighTower Advisors's portfolio in Q2 2026, its #1186 holding.
  • HighTower Advisors first reported a position in Drugs Made In America Acquisition II Corp in Q4 2025 and has held it in 3 quarters since.
  • HighTower Advisors's Drugs Made In America Acquisition II Corp position peaked at $7.82M in Q4 2025.
  • 69 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q2 2026.

Based on HighTower Advisors's 13F filing for Q2 2026, filed 5 Aug 2026.